BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mystic Pharmaceuticals Receives U.S. Patent for Intranasal Delivery Technology for Pharmaceuticals and Biologics


2/7/2013 9:53:43 AM

AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced today it has been granted U.S. Patent No. 8,377,009, “Intranasal Cartridge Devices” a novel device technology for delivering drugs and biologics into the body via the nasal route. This delivery system is based upon the company’s VersiDoser® and VRx2™ unit dose packaging and delivery platforms. Mystic’s President and CEO, Timothy Sullivan stated that, “The US market for nasal pharmaceuticals is projected to hit $4.25B by 2015 for a broad range of therapeutic drugs. Nasal vaccines will further expand this market opportunity for our technology. Our VersiDoser® and VRx2™ delivery solutions are designed to enhance the patient experience by making these products safer, easier and more convenient to use.” Applications for the company’s intranasal delivery technology include vaccines for infectious diseases such as pandemic or seasonal influenza and therapeutics for pain management, seizure, emesis, depression, hormone therapy and diabetes.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES